ECLIM-SEHOP:如何开发儿童癌症学术试验平台

Antonio Juan-Ribelles, Francisco Bautista, Adela Cañete, Alba Rubio-San-Simón, Anna Alonso-Saladrigues, Raquel Hladun, Susana Rives, Jose Luís Dapena, Jose María Fernández, Álvaro Lassaletta, Ofelia Cruz, Gemma Ramírez-Villar, Jose Luís Fuster, Cristina Diaz de Heredia, Miguel García-Ariza, Eduardo Quiroga, María del Mar Andrés, Jaime Verdú-Amorós, Antonio Molinés, Blanca Herrero, Mónica López, Catalina Márquez, María Toboso, Frencisco Lendínez, Jose Gómez Sirvent, María Tallón, Guiomar Rodríguez, Tomás Acha, Lucas Moreno, Ana Fernández-Teijeiro
{"title":"ECLIM-SEHOP:如何开发儿童癌症学术试验平台","authors":"Antonio Juan-Ribelles, Francisco Bautista, Adela Cañete, Alba Rubio-San-Simón, Anna Alonso-Saladrigues, Raquel Hladun, Susana Rives, Jose Luís Dapena, Jose María Fernández, Álvaro Lassaletta, Ofelia Cruz, Gemma Ramírez-Villar, Jose Luís Fuster, Cristina Diaz de Heredia, Miguel García-Ariza, Eduardo Quiroga, María del Mar Andrés, Jaime Verdú-Amorós, Antonio Molinés, Blanca Herrero, Mónica López, Catalina Márquez, María Toboso, Frencisco Lendínez, Jose Gómez Sirvent, María Tallón, Guiomar Rodríguez, Tomás Acha, Lucas Moreno, Ana Fernández-Teijeiro","doi":"10.1007/s12094-024-03445-0","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.</p><h3 data-test=\"abstract-sub-heading\">Discussion</h3><p>ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer\",\"authors\":\"Antonio Juan-Ribelles, Francisco Bautista, Adela Cañete, Alba Rubio-San-Simón, Anna Alonso-Saladrigues, Raquel Hladun, Susana Rives, Jose Luís Dapena, Jose María Fernández, Álvaro Lassaletta, Ofelia Cruz, Gemma Ramírez-Villar, Jose Luís Fuster, Cristina Diaz de Heredia, Miguel García-Ariza, Eduardo Quiroga, María del Mar Andrés, Jaime Verdú-Amorós, Antonio Molinés, Blanca Herrero, Mónica López, Catalina Márquez, María Toboso, Frencisco Lendínez, Jose Gómez Sirvent, María Tallón, Guiomar Rodríguez, Tomás Acha, Lucas Moreno, Ana Fernández-Teijeiro\",\"doi\":\"10.1007/s12094-024-03445-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Introduction</h3><p>ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.</p><h3 data-test=\\\"abstract-sub-heading\\\">Discussion</h3><p>ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.</p>\",\"PeriodicalId\":10166,\"journal\":{\"name\":\"Clinical and Translational Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-024-03445-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03445-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言ECLIM-SEHOP平台创建于2017年。其主要目标是建立基础设施,使西班牙能够参与儿科肿瘤学的国际学术合作临床试验、观察研究和登记。本手稿旨在描述ECLIM-SEHOP自创建以来开展的活动。方法通过查询该平台的数据库,了解由该组织整体或部分支持的研究概况。结果ECLIM-SEHOP共支持了47项研究:29项临床试验和18项观察性研究/登记,共招募了5250名患者。对 25 项研究提供了综合支持:其中 16 项试验招募了 584 名患者,9 项观察性研究/登记招募了 278 名患者。这些试验包括针对白血病、淋巴瘤、脑肿瘤和颅外实体瘤的一线研究,以及其他关键横向课题,如标示外使用靶向疗法和生存期。讨论ECLIM-SEHOP平台显著提高了国际学术临床试验的可用性和可及性,促进了儿童癌症治疗资源的集中化。尽管临床试验设置指标在逐步改善,但时间安排仍有待改进。该计划为西班牙与其他欧洲国家的存活率持平做出了贡献,而其他欧洲国家的存活率在过去存在很大差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

Introduction

ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.

Methods

The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.

Results

ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.

Discussion

ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes Emerging immunologic approaches as cancer anti-angiogenic therapies Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1